• FDA granted RMAT designation to Tenaya Therapeutics’ TN-401 gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
• Designation followed interim RIDGE-1 Phase 1b/2 data showing reduced premature ventricular contractions, fewer non-sustained ventricular tachycardias.
• Company expects additional trial data, regulatory discussion updates in 4Q 2026 as it prepares for a pivotal study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenaya Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140830PRIMZONEFULLFEED9825912) on September 14, 2026, and is solely responsible for the information contained therein.